At the heart of our efforts and investment in this complex, futuristic field is the customer, for whom we develop cost-effective biopharmaceuticals to treat life-threatening ailments.
Our pioneering efforts in biotechnology have led to the launch of three successful products in the Indian market - Glaritus (long-acting 24-hr insulin analog), Wosulin (recombinant insulin), Wepox (erythropoietin) and Biovac-B (hepatitis B vacci...
At the heart of our efforts and investment in this complex, futuristic field is the customer, for whom we develop cost-effective biopharmaceuticals to treat life-threatening ailments.
Our pioneering efforts in biotechnology have led to the launch of three successful products in the Indian market - Glaritus (long-acting 24-hr insulin analog), Wosulin (recombinant insulin), Wepox (erythropoietin) and Biovac-B (hepatitis B vaccine).
Glaritus - Wockhartd was the first Company in the world after the innovator to launch this breakthrough product. A recombinant long-acting human insulin analog, glargine (branded Glaritus) is formulated on the world-class E.Coli platform technology. Its upstream and downstream processes match international cGMP norms and Wockhardt became a name to reckon with in the biotechnology space – moving from simple biologicals to complex biologicals.
Sponsored Ad
Upgrade this company profile// Update & customize all content. Ask PharmaCompass, click HERE.
Country
INDIA
Address
Wockhardt TowersBandra Kurla Complex, Bandra (East)Mumbai 400051Maharashtra, India